Denali Therapeutics Reports Strong AVLAYAH Launch and $195M Priority Review Voucher Sale
Event summary
- AVLAYAH generated $3.6M in net product revenue in its first full quarter of commercial availability.
- Denali received $195M from the sale of a Priority Review Voucher, bringing total cash to over $1.1B.
- Two Alzheimer’s disease programs advanced into clinical development using Denali’s TransportVehicle platform.
- Zafinofusp alfa for Sanfilippo syndrome type A is on track for a 2027 BLA submission.
The big picture
Denali’s strong AVLAYAH launch and strategic sale of a Priority Review Voucher underscore its ability to monetize regulatory milestones while advancing a robust pipeline in neurodegenerative diseases. The company’s TransportVehicle platform positions it as a key player in addressing the blood-brain barrier challenge, a critical bottleneck in CNS drug development.
What we're watching
- Commercial Momentum
- Whether AVLAYAH can sustain its rapid adoption and meet projected third-quarter revenue of $10M–$12M.
- Pipeline Progress
- The pace at which Denali’s Alzheimer’s disease programs, DNL628 and DNL921, advance through clinical trials.
- Financial Strategy
- How Denali allocates its $1.1B cash position to support ongoing R&D and potential acquisitions.
Related topics